Rilpivirine-Tenofovir DF-Emtricitabine (Complera)

All References

• Allavena C, Dailly E, Reliquet V, et al. Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects. J Antimicrob Chemother. 2014;69:2804-8.
  [PubMed Abstract]
• Amiel C, Schneider V, Guessant S, et al. Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'. J Antimicrob Chemother. 2014;69:3335-9.
  [PubMed Abstract]
• Behrens G, Rijnders B, Nelson M, et al. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis. AIDS Patient Care STDS. 2014;28:168-75.
  [PubMed Abstract]
• Bernardini C, Maggiolo F. Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection. Patient Prefer Adherence. 2013;7:531-42.
  [PubMed Abstract]
• Brunetta J, Moreno Guillén S, Antinori A, et al. Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial. Patient. 2015;8:257-67.
  [PubMed Abstract]
• Cazanave C, Reigadas S, Mazubert C, et al. Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012-2014. Open Forum Infect Dis. 2015;2:ofv018.
  [PubMed Abstract]
• Charpentier C, Lê MP, Joly V, et al. Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up. PLoS One. 2015;10:e0134430.
  [PubMed Abstract]
• Cohen C, Wohl D, Arribas JR, et al. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS. 2014;28:989-97.
  [PubMed Abstract]
• Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr. 2012;60:33-42.
  [PubMed Abstract]
• Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS. 2013;27:939-50.
  [PubMed Abstract]
• Collins SE, Grant PM, Uwinkindi F, et al. A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans. Open Forum Infect Dis. 2016 Sep;3:ofw141.
  [PubMed Abstract]
• Custodio JM, Yin X, Hepner M, et al. Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection. J Clin Pharmacol. 2014;54:378-85.
  [PubMed Abstract]
• Deeks ED. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a review of its use in HIV infection. Drugs. 2014;74:2079-95.
  [PubMed Abstract]
• Di Biagio A, Riccardi N, Taramasso L, et al. Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides. Int J Antimicrob Agents. 2016;48:551-554.
  [PubMed Abstract]
• Dickinson L, Yapa HM, Jackson A, et al. Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. Antimicrob Agents Chemother. 2015;59:6080-6.
  [PubMed Abstract]
• Falcon-Neyra L, Palladino C, Navarro Gómez ML, et al. Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study. Medicine (Baltimore). 2016;95:e3842.
  [PubMed Abstract]
• Foster R, McAllister J, Read TR, et al. Single-tablet emtricitabine-rilpivirine-tenofovir as HIV postexposure prophylaxis in men who have sex with men. Clin Infect Dis. 2015;61:1336-41.
  [PubMed Abstract]
• Gantner P, Reinhart S, Partisani M, et al. Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study. HIV Med. 2015;16:132-6.
  [PubMed Abstract]
• Hodder S, Arasteh K, De Wet J, et al. Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012;13:406-15.
  [PubMed Abstract]
• Lambert-Niclot S, Allavena C, Grude M, et al. Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination. J Antimicrob Chemother. 2016;71:2248-51.
  [PubMed Abstract]
• Lyseng-Williamson KA, Scott LJ. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection. Clin Drug Investig. 2012;32:715-22.
  [PubMed Abstract]
• Mills AM, Antinori A, Clotet B, et al. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks. HIV Med. 2013;14:391-400.
  [PubMed Abstract]
• Mills AM, Cohen C, Dejesus E, et al. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. HIV Clin Trials. 2013;14:216-33.
  [PubMed Abstract]
• Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378:238-46.
  [PubMed Abstract]
• Molina JM, Clumeck N, Orkin C, Rimsky LT, Vanveggel S, Stevens M. Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials. HIV Med. 2014;15:57-62.
  [PubMed Abstract]
• Nelson MR, Elion RA, Cohen CJ, et al. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies. HIV Clin Trials. 2013;14:81-91.
  [PubMed Abstract]
• Neukam K, Espinosa N, Collado A, et al. Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study. PLoS One. 2016;11:e0155842.
  [PubMed Abstract]
• Ogbuagu O. Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients. Expert Rev Anti Infect Ther. 2016;14:1113-26.
  [PubMed Abstract]
• Palacios R, Mayorga M, Pérez-Hernández IA, et al. Lipid Changes in Virologically Suppressed HIV-Infected Patients Switching from any Antiretroviral Therapy to the Emtricitabine/Rilpivirine/Tenofovir Single Tablet: GeSida Study 8114. J Int Assoc Provid AIDS Care. 2016;15:189-93.
  [PubMed Abstract]
• Palella FJ Jr, Fisher M, Tebas P, et al. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS. 2014;28:335-44.
  [PubMed Abstract]
• Pinnetti C, Di Giambenedetto S, Maggiolo F, et al. Switching to Coformulated Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed Patients: Data From a Multicenter Cohort. J Acquir Immune Defic Syndr. 2015;70:e147-50.
  [PubMed Abstract]
• Porter DP, Daeumer M, Thielen A, et al. Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study. Viruses. 2015;7:6360-70.
  [PubMed Abstract]
• Porter DP, Kulkarni R, Fralich T, Miller MD, White KL. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects. HIV Clin Trials. 2015;16:30-8.
  [PubMed Abstract]
• Porter DP, Kulkarni R, Fralich T, Miller MD, White KL. Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110). J Acquir Immune Defic Syndr. 2014;65:318-26.
  [PubMed Abstract]
• Porter DP, Toma J, Tan Y, et al. Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study. HIV Clin Trials. 2016;17:29-37.
  [PubMed Abstract]
• Rimsky L, Van Eygen V, Hoogstoel A, et al. 96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials. Antivir Ther. 2013;18:967-77.
  [PubMed Abstract]
• Rokx C, Verbon A, Rijnders BJ. Short communication: Lipids and cardiovascular risk after switching HIV-1 patients on nevirapine and emtricitabine/tenofovir-DF to rilpivirine/emtricitabine/tenofovir-DF. AIDS Res Hum Retroviruses. 2015;31:363-7.
  [PubMed Abstract]
• Rokx C, Verbon A, Rijnders BJ. Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy. HIV Med. 2014;15:611-4.
  [PubMed Abstract]
• Ryan R, Dayaram YK, Schaible D, Coate B, Anderson D. Outcomes in older versus younger patients over 96 weeks in HIV-1- infected patients treated with rilpivirine or efavirenz in ECHO and THRIVE. Curr HIV Res. 2013;11:570-5.
  [PubMed Abstract]
• Tebas P, Sension M, Arribas J, et al. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials. Clin Infect Dis. 2014;59:425-34.
  [PubMed Abstract]
• Van Eygen V, Thys K, Van Hove C, et al. Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE. J Med Virol. 2016;88:798-806.
  [PubMed Abstract]
• van Lunzen J, Antinori A, Cohen CJ, et al. Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study. AIDS. 2016;30:251-9.
  [PubMed Abstract]
• Vingerhoets J, Rimsky L, Van Eygen V, et al. Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response. Antivir Ther. 2013;18:253-6.
  [PubMed Abstract]
• Wainberg MA. Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir. HIV AIDS (Auckl). 2013;5:41-9.
  [PubMed Abstract]
• Wilkins EL, Cohen CJ, Trottier B, et al. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment. AIDS Care. 2016;28:401-8.
  [PubMed Abstract]
• Wohl DA, Orkin C, Doroana M, et al. Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO). Antivir Ther. 2014;19:191-200.
  [PubMed Abstract]